Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $23.7600 (-1.61%) ($23.6400 - $24.5000) on Fri. Jul. 10, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.51% (three month average) | RSI | 73 | Latest Price | $23.7600(-1.61%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 3.3% a day on average for past five trading days. | Weekly Trend | TGTX advances 10.8% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(59%) ARKK(56%) IWO(56%) IBB(55%) | Factors Impacting TGTX price | TGTX will decline at least -3.255% in a week (0% probabilities). VIXM(-35%) VXX(-32%) UUP(-17%) DRIV(-4%) XLC(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.255% (StdDev 6.51%) | Hourly BBV | 0 () | Intraday Trend | -1.6% | | | |
|
5 Day Moving Average | $22.97(3.44%) | 10 Day Moving Average | $21.3(11.55%) | 20 Day Moving Average | $19.98(18.92%) | To recent high | -1.6% | To recent low | 139% | Market Cap | $3.009b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |